BD and Magnolia Medical Technologies announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes.
Under the agreement, BD and Magnolia Medical will both co-sell and co-market Magnolia Medical's Steripath and Steripath Micro Initial Specimen Diversion Device platforms, complementing the BD specimen collection portfolio, including BD Vacutainer push button and BD Vacutainer UltraTouch blood collection sets.
Steripath is an FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing accuracy. The Steripath Initial Specimen Diversion Devices divert and sequester the initial 1.5 to 2 mL of potentially contaminated blood from the sample and then collect blood for blood cultures.
To date, 20 studies have been completed supporting the clinical and cost effectiveness of Steripath. All clinical studies reported sustained contamination rates of 1% or less using Steripath and a study achieved a 31% reduction in vancomycin days of therapy.
Steripath has been adopted by hundreds of U.S. hospitals and health care systems to address the problem of blood culture contamination, which can lead to sepsis misdiagnosis resulting in unnecessary, prolonged, and harmful antibiotic treatment, extended length of hospital stay, false-positive CLABSIs, and wasted health care resources.
